Cytovation appoints Olav Hellebø to board of directors

Betsy Goodfellow | July 5, 2023 | Appointment | Business Services Cytovation, Olav Hellebø, Oncology, appointment, board of directors 

Cytovation ASA, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has appointed Olav Hellebø to its board of directors.

Hellebø brings with him extensive leadership experience from US- and Europe-based pharmaceutical and biotechnology companies, having previously acted as chief executive officer at ReNeuron and Clavis Pharma. Prior to these roles, Hellebø headed up the global immunology franchise at UCB Pharma, also having worked as head of UK commercial operations at Novartis. He has also held senior roles at Schering-Plough.

Currently, Hellebø serves on the board of Antev, a UK-based private biotech company with a focus on prostate cancer.

Stein Christian Mohn, chairman at Cytovation, stated: “We are very pleased to welcome Olav to our board of directors. We believe that his extensive and broad-ranging experience in the industry will prove invaluable for the advancement of CyPep-1 and the continuing growth of the company as we continue to make excellent progress in our ongoing clinical programme both in Europe and the US.”

Commenting on his new role, Hellebø added: “CyPep-1 has great potential as an innovative treatment for solid tumours where there is significant unmet medical need despite recent advances in cancer treatment. I look forward to working with the talented team at Cytovation to help bring this unique therapy to patients.”

Betsy Goodfellow

Related Content


Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …


Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …


Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content